• Profile

Phase 1 study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer

Journal of Clinical Oncology Nov 20, 2019

Danila DC, Szmulewitz RZ, Vaishampayan U, et al. - Researchers examined the safety and activity of DSTP3086S, a humanized immunoglobulin G1 anti-six-transmembrane epithelial antigen of the prostate 1 (STEAP1) monoclonal antibody linked to the potent antimitotic agent monomethyl auristatin E, in patients with metastatic castration-resistant prostate cancer. In a 3 + 3 dose escalation study, 77 patients were given DSTP3086S (0.3 to 2.8 mg/kg intravenously) once every 3 weeks, and seven were treated weekly. Outcomes revealed an acceptable safety profile of DSTP3086S at the recommended phase II dose level of 2.4 mg/kg once every 3 weeks. They observed antitumor activity at doses between 2.25 and 2.8 mg/kg once every 3 weeks. This suggests the potential benefit of managing STEAP1-expressing metastatic castration-resistant prostate cancer with an STEAP1-targeting antibody-drug conjugate.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen